Hualan Biological Bacterin Inc. engages in the research, development, production, and sale of vaccines in China. It offers influenza virus split vaccines, quadrivalent influenza virus split vaccines, H1N1 influenza virus split vaccines, ACYW135 meningococcal polysaccharide plague vaccines, recombinant hepatitis B vaccines, and group A and C meningococcal polysaccharide vaccines, as well as genetic engineering vaccines for human use. The company was founded in 2005 and is based in Xinxiang, China.
Stock data | 2024 | Change |
---|---|---|
Price | $2.59 | N/A |
Market Cap | $1.55B | N/A |
Shares Outstanding | 600.01M | N/A |
Employees | 772.00 | N/A |